Unity Biotechnology (NASDAQ:UBX – Get Free Report) issued its earnings results on Monday. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02, Zacks reports.
Unity Biotechnology Price Performance
Shares of NASDAQ UBX opened at $1.21 on Wednesday. Unity Biotechnology has a 1 year low of $1.12 and a 1 year high of $2.26. The firm has a 50-day moving average of $1.44 and a 200 day moving average of $1.47. The stock has a market cap of $20.39 million, a P/E ratio of -0.92 and a beta of 0.83.
Wall Street Analyst Weigh In
Several brokerages have weighed in on UBX. Rodman & Renshaw started coverage on Unity Biotechnology in a research report on Thursday, August 22nd. They issued a “buy” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Unity Biotechnology in a research report on Thursday, August 8th.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Read More
- Five stocks we like better than Unity Biotechnology
- Using the MarketBeat Dividend Yield Calculator
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
- Following Congress Stock Trades
- Is NVIDIA-Backed SoundHound AI a Buy Ahead of Nov. 12 Earnings?
- How to Calculate Inflation Rate
- Gold Prices on the Rise: Will Demand Push New Highs in 2025?
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
